KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Operating Expenses (2016 - 2025)

West Pharmaceutical Services' Operating Expenses history spans 17 years, with the latest figure at $128.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 24.08% year-over-year to $128.8 million; the TTM value through Dec 2025 reached $467.9 million, up 14.79%, while the annual FY2025 figure was $467.9 million, 14.79% up from the prior year.
  • Operating Expenses for Q4 2025 was $128.8 million at West Pharmaceutical Services, up from $119.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $128.8 million in Q4 2025 and bottomed at $79.9 million in Q3 2022.
  • The 5-year median for Operating Expenses is $104.3 million (2024), against an average of $104.4 million.
  • The largest annual shift saw Operating Expenses dropped 23.9% in 2022 before it soared 31.91% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $111.7 million in 2021, then dropped by 9.04% to $101.6 million in 2022, then rose by 6.69% to $108.4 million in 2023, then fell by 4.24% to $103.8 million in 2024, then rose by 24.08% to $128.8 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Operating Expenses are $128.8 million (Q4 2025), $119.8 million (Q3 2025), and $115.0 million (Q2 2025).